Your opportunity to receive
an ophthalmology research or fellowship/training grant
To fund research initiatives that advance scientific understanding of retinal diseases
To encourage the development of the next generation of retinal experts
To improve treatment outcomes and patient quality of life through effective management of retinal diseases
As we are all painfully aware, 2020 has been an exceptionally challenging year with the coronavirus pandemic. This has caused disruption to the Global Ophthalmology Awards Program, with many research projects significantly delayed or postponed for 2021.
As a consequence, Bayer have made the difficult decision to defer the GOAP 2021 cycle until the pandemic eases and to adapt it to the new environment when we have a clearer idea of the emerging conditions.
"GOAP presents a wonderful opportunity to seek funding for your innovative research. Since its inception in 2012, 70 clinical investigators and basic researchers from around the globe have utilized their GOAP-awarded grants to advance the field of ophthalmology, with the ultimate goal of improving eye care and preserving vision for patients throughout the world. We look forward to receiving your grant application submissions."
Professor Quan Dong Nguyen
(Co-chair of the Grants Review and Awards Committee)
About Global Ophthalmology Awards Program (GOAP)
- Established by Bayer in 2012
- Designed to support innovative research in retinal disease globally, awarding grants of up to US$50,000
- Since 2012, 82 grants totalling US$4.05 million have been awarded to support a range of innovative ophthalmology research projects
Who is Bayer?
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at pharma.bayer.com.
The Global Ophthalmology Awards Program (GOAP) is an initiative instituted by Bayer that supports research and training in retinal ophthalmology with the aim of advancing the scientific understanding and clinical management of ophthalmic disorders. Through research and training grants the program seeks to provide opportunities for ophthalmology healthcare professionals that will ultimately lead to improved treatment and management for the world’s ophthalmology patients.
The GOAP demonstrates Bayer’s commitment to the global ophthalmic disorders community and to advancing state-of-the-art ophthalmic care.
Controversies in Ophthalmology (COPHy) congress and Sociedad Panamericana de Retina y Vítreo (SPRV)– our GOAP 2020 Awards Partners
We are extremely pleased to announce that the organizers of the highly attended Controversies in Ophthalmology (COPHy) congress and Sociedad Panamericana de Retina y Vítreo (SPRV) have kindly offered to honour this year’s awardees. During these congresses, awardees will be presented with their official award trophy.
COPHy AA in Bangkok and COPHy EU in Lisbon will be devoted to evidence-based debates and discussions amongst session moderators, speakers and the audience, all of whom will examine and analyze the most relevant and controversial issues raised during the course of 2019 and 2020 within the field of ophthalmology. This educational Congress will continue to discuss controversies in Anterior Segment, Glaucoma, and Retina, as well as other areas of ophthalmology, such as neuro-ophthalmology, ocular imaging, and uveitis. Each Congress will emphasize issues related to the region in terms of diagnostics, distinctive responses to treatments and typical complications.